Pathological Complete Response and Successful Conversion Hepatectomy in Initially Unresectable Giant Hepatocellular Carcinoma Following Triple Therapy With HAIC , Bevacizumab, and Tislelizumab: A Case Report
Clinical Case Reports · 2026-11 · 14 (11)
DOI: 10.1002/ccr3.73835 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical Case Reports, online erschienen am 04.11.2026. Verfasst von Qing Ye und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chin…. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Severe future liver remnant (FLR) deficiency frequently renders giant hepatocellular carcinoma (HCC) unresectable. We report a 48‐year‐old man with an unresectable 23.5‐cm giant HCC (Couinaud segments 4/5/8; baseline serum alpha‐fetoprotein (AFP), 1036.65 μg/L). Initially requiring an extended right trisectionectomy with an FLR/standard liver volume (SLV) ratio of only 36.58% (450 mL). Following three cycles of mFOLFOX‐HAIC, bevacizumab, and tislelizumab, restaging computed tomography (CT) showed tumor regression to 9.0 cm in maximum diameter (a 61.7% reduction), corresponding to a partial response (PR) according to the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1), and a complete response (CR) according to the modified RECIST (mRECIST), an increase in FLR volume to 733 mL (FLR/SLV: 59.58%), and an AFP decline to 115.00 μg/L. Crucially, tumor clearance from segment 4 and separation from the right portal pedicle enabled surgical downstaging to a parenchymal‐sparing anatomical right anterior sectionectomy (S5/8). R0 resection was achieved, with histopathology confirming a pathological complete response (pCR; 100% coagulative necrosis). Postoperatively, serum AFP normalized to 5.60 μg/L, and the patient remains recurrence‐free at 22 months. This case illustrates that tumor regression during triple therapy may be accompanied by increased FLR volume and improved anatomical separation from the right portal pedicle, potentially enabling a more limited resection without portal vein embolization.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine Guangzhou China.
- The Second Clinical College of Guangzhou University of Chinese Medicine Guangzhou China.
ORCID-Profile: Junming He, Huilan Zeng, Jiaqiang Mo
Zitieren
APA
Ye, Q., Wang, J., He, J., Peng, J., Zeng, H., & Mo, J. (2026). Pathological Complete Response and Successful Conversion Hepatectomy in Initially Unresectable Giant Hepatocellular Carcinoma Following Triple Therapy With HAIC , Bevacizumab, and Tislelizumab: A Case Report. Clinical Case Reports, 14(11). https://doi.org/10.1002/ccr3.73835
Vancouver
Ye Q, Wang J, He J, Peng J, Zeng H, Mo J. Pathological Complete Response and Successful Conversion Hepatectomy in Initially Unresectable Giant Hepatocellular Carcinoma Following Triple Therapy With HAIC , Bevacizumab, and Tislelizumab: A Case Report. Clinical Case Reports. 2026;14(11). doi:10.1002/ccr3.73835
BibTeX
@article{Ye2026,
author = {Ye, Qing and Wang, Jiamin and He, Junming and Peng, Jianxin and Zeng, Huilan and Mo, Jiaqiang},
title = {Pathological Complete Response and Successful Conversion Hepatectomy in Initially Unresectable Giant Hepatocellular Carcinoma Following Triple Therapy With HAIC , Bevacizumab, and Tislelizumab: A Case Report},
journal = {Clinical Case Reports},
year = {2026},
volume = {14},
number = {11},
doi = {10.1002/ccr3.73835}
}
EUVIMED